NCT06652958View on ClinicalTrials.gov

A Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults and Persons With HIV

PHASE1RecruitingINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

October 2, 2024

Primary Completion Date

February 1, 2027

Study Completion Date

February 3, 2027

Conditions
HIV Infections
Interventions
BIOLOGICAL

VH4527079

VH4527079 solution for injection or infusion will be administered either by SC injection or IV infusion respectively.

Trial Locations (2)

78744

NOT_YET_RECRUITING

GSK Investigational Site, Austin

89113

RECRUITING

GSK Investigational Site, Las Vegas

Sponsors

Lead Sponsor

ViiV Healthcare
All Listed Sponsors
lead

ViiV Healthcare

INDUSTRY

NCT06652958 - A Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults and Persons With HIV | Biotech Hunter | Biotech Hunter